RU2506092C2 - Способ активирования лечения ран - Google Patents

Способ активирования лечения ран Download PDF

Info

Publication number
RU2506092C2
RU2506092C2 RU2010151472/15A RU2010151472A RU2506092C2 RU 2506092 C2 RU2506092 C2 RU 2506092C2 RU 2010151472/15 A RU2010151472/15 A RU 2010151472/15A RU 2010151472 A RU2010151472 A RU 2010151472A RU 2506092 C2 RU2506092 C2 RU 2506092C2
Authority
RU
Russia
Prior art keywords
relaxin
wound
skin
wounds
subject
Prior art date
Application number
RU2010151472/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2010151472A (ru
Inventor
Деннис Р. Стьюарт
Original Assignee
Кортера, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41319048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2506092(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Кортера, Инк. filed Critical Кортера, Инк.
Publication of RU2010151472A publication Critical patent/RU2010151472A/ru
Application granted granted Critical
Publication of RU2506092C2 publication Critical patent/RU2506092C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
RU2010151472/15A 2008-05-16 2009-05-13 Способ активирования лечения ран RU2506092C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12794708P 2008-05-16 2008-05-16
US61/127,947 2008-05-16
PCT/US2009/043854 WO2009140433A1 (en) 2008-05-16 2009-05-13 Method of promoting wound healing

Publications (2)

Publication Number Publication Date
RU2010151472A RU2010151472A (ru) 2012-06-27
RU2506092C2 true RU2506092C2 (ru) 2014-02-10

Family

ID=41319048

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010151472/15A RU2506092C2 (ru) 2008-05-16 2009-05-13 Способ активирования лечения ран

Country Status (10)

Country Link
US (2) US20100041603A1 (enExample)
EP (1) EP2278993A4 (enExample)
JP (3) JP2011520902A (enExample)
CN (2) CN105688192A (enExample)
AU (1) AU2009246333B2 (enExample)
BR (1) BRPI0912560A2 (enExample)
CA (1) CA2724308C (enExample)
MX (1) MX2010012454A (enExample)
RU (1) RU2506092C2 (enExample)
WO (1) WO2009140433A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2766032A4 (en) * 2011-10-13 2015-04-29 Thomas Gadek TOPICAL FORMULATIONS OF PEPTIDES CHÉMÉRINE C15 FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS
MX2015001488A (es) * 2012-07-31 2015-04-08 Novartis Ag Tratamiento de la inflamacion utilizando serelaxina.
BR112016006426A2 (pt) * 2013-09-26 2017-08-01 Galderma Sa método de tratamento de cicatrizes cutâneas atróficas
CN106999549A (zh) * 2014-12-09 2017-08-01 加利福尼亚大学董事会 促进组织愈合和修复的方法
DK3387019T3 (da) 2015-12-09 2022-01-10 Scripps Research Inst Relaxin-immunoglobulinfusionsproteiner og anvendelsesfremgangsmåder
JP6955736B2 (ja) * 2016-09-14 2021-10-27 ヤンマーパワーテクノロジー株式会社 水生生物の飼育装置
MX2019008449A (es) 2017-02-08 2019-09-09 Bristol Myers Squibb Co Polipetidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3003917A (en) * 1959-01-14 1961-10-10 Nat Drug Co Wound healing composition
US4969880A (en) * 1989-04-03 1990-11-13 Zamierowski David S Wound dressing and treatment method
US5192743A (en) * 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
US6176854B1 (en) * 1997-10-08 2001-01-23 Robert Roy Cone Percutaneous laser treatment
US20040157771A1 (en) * 2002-02-28 2004-08-12 Bird Timothy A. Rank-ligand-induced sodium/proton antiporter polypeptides

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH661662A5 (en) * 1984-04-16 1987-08-14 Georg L Prof Dr Floersheim Product for the treatment of the skin and of the connective tissue
US4863733A (en) * 1985-08-28 1989-09-05 Startz Jack P Method of preparing treatment compositions for use in plastic or cosmetic surgery
WO1989007945A1 (en) * 1988-02-26 1989-09-08 Genentech, Inc. Human relaxin formulation
US5100396A (en) * 1989-04-03 1992-03-31 Zamierowski David S Fluidic connection system and method
US5658956A (en) * 1991-03-01 1997-08-19 Warner-Lambert Company Bioadhesive-wound healing compositions and methods for preparing and using same
WO1996033733A1 (en) * 1995-04-25 1996-10-31 Fuji Yakuhin Kogyo Kabushiki Kaisha Novel remedy for skin deficiencies
WO1997006814A1 (en) * 1995-08-15 1997-02-27 Connective Therapeutics, Inc. Method of promoting angiogenesis
US7550143B2 (en) * 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US7534866B2 (en) * 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
EP1253929B1 (en) * 2000-02-09 2007-05-23 BAS Medical, Inc. Use of relaxin to treat diseases related to vasoconstriction
US20030088884A1 (en) * 2001-08-17 2003-05-08 Hsu Sheau Yu Mammalian relaxin receptors
US7776854B2 (en) * 2001-12-07 2010-08-17 Merck Serono Sa Benzazole derivatives for the treatment of scleroderma
US7591994B2 (en) * 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US8877901B2 (en) * 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
EP1572242B1 (en) * 2002-12-13 2014-04-16 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
US20040266743A1 (en) * 2003-05-09 2004-12-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
US7738952B2 (en) * 2003-06-09 2010-06-15 Palo Alto Investors Treatment of conditions through modulation of the autonomic nervous system
US7149574B2 (en) * 2003-06-09 2006-12-12 Palo Alto Investors Treatment of conditions through electrical modulation of the autonomic nervous system
AU2003903124A0 (en) * 2003-06-20 2003-07-10 Mark Del Borgo Analogues of heteromeric proteins
US20050153885A1 (en) * 2003-10-08 2005-07-14 Yun Anthony J. Treatment of conditions through modulation of the autonomic nervous system
US8569277B2 (en) * 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
US20060052304A1 (en) * 2004-09-02 2006-03-09 Bas Medical, Inc. Method for remodeling bone and related sutures
EP1846443A4 (en) * 2005-01-07 2008-07-23 Glaxo Group Ltd NEW USE
CN101484182B (zh) * 2005-04-06 2014-06-11 Ibc药品公司 由同二聚体、同四聚体或二聚体的二聚体组成的稳定连接复合体的生产方法及用途
CN101534865A (zh) * 2005-10-19 2009-09-16 Ibc药品公司 生物活性装配体的制备方法及其用途
PT1978919E (pt) * 2005-12-15 2010-05-24 Lucedio Greci Síntese de um novo antioxidante de nitróxido e métodos de utilização em composições cosméticas e dermatológicas

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3003917A (en) * 1959-01-14 1961-10-10 Nat Drug Co Wound healing composition
US4969880A (en) * 1989-04-03 1990-11-13 Zamierowski David S Wound dressing and treatment method
US5192743A (en) * 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
US6176854B1 (en) * 1997-10-08 2001-01-23 Robert Roy Cone Percutaneous laser treatment
US20040157771A1 (en) * 2002-02-28 2004-08-12 Bird Timothy A. Rank-ligand-induced sodium/proton antiporter polypeptides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MILLAR LK, REINY R, et al. Relaxin causes proliferation of human amniotic epithelium by stimulation of insulin-like growth factor-II. Am J Obstet Gynecol. 2003 Jan; 188(1):234-41. *
MILLAR LK, REINY R, et al. Relaxin causes proliferation of human amniotic epithelium by stimulation of insulin-like growth factor-II. Am J Obstet Gynecol. 2003 Jan; 188(1):234-41. SAMUEL CS. et al. Relaxin is a key mediator of prostate growth and male reproductive tract development. Lab Invest. 2003 Jul;83(7):1055-67. Lab Invest. 2003 Jul; 83(7):1055-67. *
ONO I, AKASAKA Y. et al. Basic fibroblast growth factor reduces scar formation in acute incisional wounds. Wound Repair Regen. 2007 Sep-Oct; 15(5):617-23.Wound Repair Regen. 2007 Sep-Oct; 15(5):617-23. *
SAMUEL CS. et al. Relaxin is a key mediator of prostate growth and male reproductive tract development. Lab Invest. 2003 Jul;83(7):1055-67. Lab Invest. 2003 Jul; 83(7):1055-67. *

Also Published As

Publication number Publication date
BRPI0912560A2 (pt) 2019-09-24
EP2278993A4 (en) 2012-09-12
CN102026656A (zh) 2011-04-20
AU2009246333A1 (en) 2009-11-19
MX2010012454A (es) 2011-03-29
RU2010151472A (ru) 2012-06-27
CA2724308A1 (en) 2009-11-19
JP2014129392A (ja) 2014-07-10
WO2009140433A1 (en) 2009-11-19
US20100041603A1 (en) 2010-02-18
AU2009246333B2 (en) 2013-05-09
JP2016179990A (ja) 2016-10-13
CA2724308C (en) 2016-08-16
JP2011520902A (ja) 2011-07-21
EP2278993A1 (en) 2011-02-02
US20110092439A1 (en) 2011-04-21
CN105688192A (zh) 2016-06-22

Similar Documents

Publication Publication Date Title
RU2506092C2 (ru) Способ активирования лечения ран
KR20180114911A (ko) 침습 및 비침습 시술적 피부 관리를 위한 조성물 및 방법
BR112012001491A2 (pt) composição de preparação externa para pele
US9023792B2 (en) Method for treating keloid and hypertrophic scars by administration of bFGF
US12357674B2 (en) Methods for promoting wound healing and hair growth comprising GDNF administration
JP5300281B2 (ja) 創傷治療剤および創傷治療用組成物
CN107446018B (zh) 促进伤口愈合的肽及其应用
CN115991758B (zh) 一种促进糖尿病创面愈合的珍珠粉多肽及其应用
KR101917026B1 (ko) 피부 주름 개선 또는 예방용 화장료 조성물
KR20240117782A (ko) 켈로이드 치료를 위한 피부 패치와 주사 치료제 조성물
AU2013204203A1 (en) Method of promoting wound healing
JP2023552515A (ja) 創傷を治療するための組成物および方法
HK1151968A (en) Agent for treating skin aging and scars
HK1151968B (en) Agent for treating skin aging and scars

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20180514